Every material Form 8-K Exelixis filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Exelixis reported third-quarter 2024 total revenues of $539.5 million, up from $471.9 million a year earlier, and GAAP diluted earnings of $0.40 per share, up from $0.00. The company raised its 2024 total revenue and net product revenue guidance, and its quarter included a $51.7 million non-cash impairment charge on leased facilities not in use.
Q3 2024 total revenues were $539.5 million versus $471.9 million in Q3 2023; net product revenues were $478.1 million.
GAAP diluted EPS was $0.40 versus $0.00 a year earlier; non-GAAP diluted EPS was $0.47 versus $0.10.
2024 total revenue guidance was raised to $2.150 billion-$2.200 billion from $1.975 billion-$2.075 billion.
Exelixis reported second quarter 2024 total revenues of $637.2 million, up from $469.8 million a year earlier, and GAAP diluted EPS of $0.77, up from $0.25. The Board also authorized up to $500 million in additional stock repurchases through the end of 2025, and the company updated its full-year 2024 financial guidance.
Q2 2024 total revenues $637.2 million vs. $469.8 million in Q2 2023; net product revenues $437.6 million vs. $409.6 million
GAAP diluted EPS $0.77 vs. $0.25; non-GAAP diluted EPS $0.84 vs. $0.31
Board authorized repurchase of up to $500 million of common stock through the end of 2025; the $450 million 2024 program was completed
2024 total revenues guidance of $1.975 billion to $2.075 billion; FDA accepted cabozantinib sNDA for advanced NET with PDUFA target date of April 3, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Exelixis filing is on SEC EDGAR ↗. 8-K briefs of other companies →